AstraZeneca appoints Josep Baselga to head R&D for Oncology

by Gemma Escarré,

AstraZeneca has announced organisational changes to support continued scientific innovation and commercial success in the main therapy areas as the company enters a new phase in its strategic development.

Included in the changes will be the arrival of the world-renowned oncology scientist, Josep Baselga. He was most recently Physician-in-Chief at Memorial Sloan Kettering Cancer Center. Prior to this, he was Associate Director at the Massachusetts General Hospital Cancer Center and Founding Director of the Vall d‘Hebron Institute of Oncology (VHIO) in Barcelona.

Currently, AstraZeneca is focused in three therapy areas: oncology; cardiovascular; renal, metabolism and respiratory. In Barcelona, the biopharmaceutical company has a specialized R&D medicine center in the respiratory area (CataloniaBio & HealthTech member).

More information

Photo by Juliana Thomas - Memorial Sloan Kettering Cancer Center


To comment, please login or create an account